 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that YMAB's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Y-mAbs Therapeutics (YMAB, $6.21) RSI Indicator left the overbought zone on November 30, 2023

This is a signal that YMAB's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Y-mAbs Therapeutics (YMAB, $5.54) Stochastic Oscillator left the overbought zone on November 27, 2023

This indicator may be signaling YMAB's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Y-mAbs Therapeutics (YMAB, $5.45) entered Uptrend as Momentum indicator ascends above 0 level on Nov 22, 2023

This is a Bullish indicator signaling YMAB's price could rise from here. Traders may explore going long the stock or buying call options...

Y-mAbs Therapeutics (YMAB, $5.45) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 22, 2023

This price move could indicate a change in the trend, and may be a buy signal for investors...

Y-mAbs Therapeutics (YMAB, $5.45) price moved above its 50-day Moving Average on November 22, 2023

This price move could indicate a change in the trend, and may be a sell signal for investors...

Y-mAbs Therapeutics (YMAB, $5.26) price exceeded its 50-day Moving Average on November 20, 2023

Y-mAbs Therapeutics (YMAB, $5.43) price moved above its 50-day Moving Average on November 17, 2023

Y-mAbs Therapeutics (YMAB, $5.25) price exceeded its 50-day Moving Average on November 15, 2023

This indicator may be signaling that YMAB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Y-mAbs Therapeutics (YMAB, $5.25) entered Downtrend as Momentum indicator drops below 0 level on Nov 15, 2023

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Y-Mabs Therapeutics (YMAB Research Report), with a price target of $11.00. Rob...

DANYELZA Sales Projection and Financial Outlook for Y-Mabs Therapeutics: A Comprehensive Buy Rating Analysis

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Watchers	558
52-Wk Low	$2.70
52-Wk High	$10.95

Market Cap	$270.89M
Volume (M)	181,611.00
52-Wk High	$10.95
52-Wk Low	$2.70

YMAB Y-Mabs Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals